<code id='9C516F1262'></code><style id='9C516F1262'></style>
    • <acronym id='9C516F1262'></acronym>
      <center id='9C516F1262'><center id='9C516F1262'><tfoot id='9C516F1262'></tfoot></center><abbr id='9C516F1262'><dir id='9C516F1262'><tfoot id='9C516F1262'></tfoot><noframes id='9C516F1262'>

    • <optgroup id='9C516F1262'><strike id='9C516F1262'><sup id='9C516F1262'></sup></strike><code id='9C516F1262'></code></optgroup>
        1. <b id='9C516F1262'><label id='9C516F1262'><select id='9C516F1262'><dt id='9C516F1262'><span id='9C516F1262'></span></dt></select></label></b><u id='9C516F1262'></u>
          <i id='9C516F1262'><strike id='9C516F1262'><tt id='9C516F1262'><pre id='9C516F1262'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:knowledge    Page View:5

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In